Novel clinical approaches in monoclonal antibody-based management in colorectal cancer patients: Radioimmunoguided surgery and antigen augmentation

Seminars in Surgical Oncology

Volumn 15, Issue 4, 1998, Pages 254-262

  Roselli, Mario ^a   Buonomo, Oreste ^a   Piazza, Antonina ^b   Guadagni, Fiorella ^c   Vecchione, Aldo ^d   Brunetti, Ercole ^e   Cipriani, Cesidio ^f   Amadei, Giuseppe ^a   Nieroda, Carol ^g   Greiner, John W ^g   Casciani, Carlo U ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CNR   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e FATEBENEFRATELLI HOSPITAL   (Italy)

^f S EUGENIO HOSPITAL   (Italy)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biological response modifiers; Colonic neoplasms; Colorectal neoplasms; Glycoproteins; Immunohistochemistry; Interferons; Lymph nodes; Lymphatic metastasis; Monoclonal antibodies; Mucins; Neoplasm staging; Polymerase chain reaction; Radioimmuno detection; Radioimmunoguided surgery; Radioisotopes; Radiopharmaceuticals; Up regulation

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; CARCINOEMBRYONIC ANTIBODY; GAMMA INTERFERON; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY CC49;

ANTIGEN EXPRESSION; ANTIGENIC VARIATION; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; COLORECTAL CANCER; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHOCYTE FUNCTION; OCCULT CANCER; PRIORITY JOURNAL; RADIOIMMUNOLOGY; RADIOSURGERY; SCINTISCANNING; TARGET CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; CYTOKINES; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON ALFA-2A; NEOPLASM STAGING; RADIOIMMUNODETECTION; RADIOISOTOPES; RECTAL NEOPLASMS;

EID: 7844237897     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199812)15:4<254::AID-SSU14>3.0.CO;2-V     Document Type: Conference Paper

References (49)

1. Schottenfeld D: Epidemiology. In: Cohen AM, Winawer SJ (eds): "Cancer of the colon, rectum and anus." New York: McGraw-Hill; 1995. p.11-24.
2. Noguchi M, Miyazaki I: Extended lymph node dissection in gastrointestinal cancer [Review] J Surg Oncol 1997;65:57-65.
3. Gardner B: It's time to stop the pendulum [editorial]. J Surg Oncol 1994,57:1-2.
4. Thurston MO, Mojzisik CM: History and development of RIGS. Semin Colon Rectal Surg 1995;6:185-191.
5. Kim JA: Observations on the immunologic basis of the radioimmunoguided surgery system. Semin Colon Rectal Surg 1995;6:202-206.
6. Hitchcook CL: RIGS and staging of colorectal carcinoma. Semin Colon Rectal Surg 1995;6:207-216.
7. Bertsch DJ, Burak WE Jr, Young DC, et al: Radioimmunoguided surgery system improves survival for patients with recurrent colorectal cancer [Review]. Surgery 1995;118:634-639.
8. Bertsch DJ, Burak WE Jr. Young DC, et al: Radioimmunoguided surgery for colorectal cancer. Ann Surg Oncol 1996;3:310-316.
9. Burek WE Jr, Schneebaum S: RIGS recurrent clinical trials and application. Semin Colon Rectal Surg 1995;6:226-233.
10. Arnold MW, Young DC. Hitchcook CL, et al: Radioimmunoguided surgery in primary colorectal carcinoma: an intraoperative prognostic tool and adjuvant to traditional staging. Am J Surg 1995;170:315-318.
11. Martinez D, Barbera-Guillem E, La Valle G, et al: Radioimmunoguided surgery for gastrointestinal malignancies: an analysis of 14 years of clinical experience. Cancer Control 1997; 4:505-516.
12. Arnold MW, Schneebaum S, Berens A, et al: Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg 1992;216:627-632.
13. Cohen AM, Martin EW Jr, Lavery I, et al: Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 1991;12:349-352.
14. Schneebaum S, Ritter DC, Burak WE Jr: RIGS primary clinical trials. Semin Colon Rectal Surg 1995;6:217-225.
15. Schneebaum S, Arnold MW, Houchens DP, et al: The importance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer 1995;75:2809-2817.
16. Mariani-Costantini R, Muraro R, Ficari F, et al: Immunohitochemical evidence of immune responses to tumor-associated antigens in lymph nodes of colon carcinoma patients. Cancer 1991;67:2880-2886.
17. Adachi W, Sugenoya A, Iida F: Immune competent cells of regional lymph nodes in colorectal cancer patients. I. Flow cytometric analysis of lymphocyte sub-population. J Surg Oncol 1991;46:110-116.
18. Triozzi PL, Kim JA, Aldrich W, et al: Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody. Cancer 1994;73:580-589.
19. Roselli M, Guadagni F, Buonomo O, et al: Systemic administration of recombinant interferon-alpha in carcinoma patients upregulates the expression of the carcinoma-associated antigens glycoprotein-72 and carcinoembryonic antigen. J Clin Oncol 1996;14:2031-2042.
20. Itzkowitz SH, Bloom EJ, Kokal WA, et al: Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients Cancer 1990;66:1960-1966.
21. Ogata S, Maimonis PJ, Itzkowitz SH: Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res 1992;52:4741-1746.
22. Fung PY, Lonenecker BM: Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 1991;51:1170-1176.
23. Greenson JK, Isenhart CE, Rice R, et al: Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994;73:563-569.
24. rd Conference of the American Association of Cancer Research; 1992 May 20-23; San Diego (CA). Baltimore: Waverly: 1992. Volume 33:317.
25. Bertoglio S, Percivale P, Gambin C, et al: Cytokeratin immunostaining reveals micrometastasis in negative hematoxylin-eosin lymph nodes of resected Stage I-II (pT2-pT3) colorectal cancer. J Chemother 1997;9:119-120.
26. Haboubi NY, Clark P, Kaftan SM, Scholfield PF: The importance of combining xylene clearance and immunohistochemistry in the accurate staging of colorectal carcinoma. J R Soc Med 1992;85:386-388.
27. Mori M, Mimori K, Ueo H, et al: Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J Clin Oncol 1998;16:128-132.
28. Nakamori S, Kameyama M, Furukawa H, et al: Genetic detection of colorectal cancer cells in circulation and lymph nodes. Dis Colon Rectum 1997;40(10 Suppl):S29-S36.
29. Abdel Nabi H, Doerr RJ, Balu D, et al: Gamma probe assisted ex vivo detection of small lymph node metastases following the administration Indium-111-labeled monoclonal antibodies to colorectal cancers. J Nucl Med 1993;34:1818-1822.
30. Attallah MM, Needy CF, Noguchi PD, Elisberg BL: Enhancement of carcinoembryonic antigen expression by interferon. Int J Cancer 1979;24:49-52.
31. Greiner JW, Hand PH, Noguchi P, et al: Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res 1984;44:3208-3214.
32. Borden EC: Augmented tumor-associated antigen expression by interferons. J Natl Cancer Inst 1988;80:148-149.
33. Kantor J, Tran R, Greiner J, et al: Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human gamma-interferon. Cancer Res 1989;49:2651-2655.
34. Guadagni F, Witt PL, Robbins PF, et al: Regulation of carcinoembryonic antigen expression in differential human colorectal tumor cells by interferon-gamma Cancer Res 1990;50:6248-6255.
35. Borden EC: Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma [Review]. Semin Oncol 1994;21(6 Suppl 14):14-22.
36. Bouroncle BA: Thirty-five years in the progress of hairy cell leukemia [Review]. Leuk Lymphoma 1994;14 Suppl 1:1-12.
37. Buzaid AC, Legha SS: Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma [Review], Semin Oncol 1994;21(6 Suppl 14):23-28.
38. Nieroda CA, Milenic DE, Carrasquillo JA, et al: Improved tumor radioimmunodetection using a single chain Fv and gamma-interferon: potential clinical applications for radioimmunoguided surgery and gamma scanning. Cancer Res 1995;55:2858-2865.
39. Guadagni F, Schlom J, Johnston WW, et al: Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 1989,81.502-512.
40. Gremer JW, Fischer PB, Pestka S, Schlom J: Differential effects of recombinant human leukocyte interferons on cells surface antigen expression. Cancer Res 1986;46:4984-4990.
41. Greiner JW, Ullmann CD, Nieroda C, Qi CF: Improved immunotherapeutic efficacy of an anti-carcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon. Cancer Res 1993;53:600-608.
42. Greiner JW, Guadagni F, Goldstein D, et al: Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered Interferon. Cancer Res 1991;51:4155-4163.
43. Greiner JW, Guadagni F, Goldstein D, et al: Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 1991;10:735-746.
44. Winzelberg GG, Grossman SJ, Rizk S, et al: Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer correlated with computed tomography, surgery, histopathology, immunobiolosy. and human immune response. Cancer 1992; 69:1656-1663.
45. Mahvi DM, Madsen JA, Win PL, Sondel PM: Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer. Cancer Immunol Immunother 1995;40:311-314.
46. Rosenblum MG, Lamki LM, Murray JL, et al: Interferon-induced changes in pharmacokinetics and tumor uptake of 111 In-labeled anti-melanoma antibody 96.5 in melanoma patients. J Nati Cancer Inst 1988;80:160-165.
47. Murray JL, Macey DJ, Grant EJ, et al: Enhanced TAG-72 expression and tumor uptake of radiolabeled antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Cancer Res 1995;55(23 Suppl):5925S-5928S.
48. Guadagni F, Schlom J, Pothen S, et al: Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol Immunother 1988;26: 222-230.
49. Nieroda C, Pestka S, Schlom J, et al: Interferon-omega augments major histocompatibility and human tumor-associated antigen expression. Mol Cell Differentiation 1996;4:335-351.